Current Status of PSMA‑Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization
10.1007/s13139-022-00764-4
- Author:
So Won OH
1
;
Minseok SUH
;
Gi Jeong CHEON
Author Information
1. Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul 07061, Korea
- Publication Type:REVIEW
- From:Nuclear Medicine and Molecular Imaging
2022;56(6):263-281
- CountryRepublic of Korea
- Language:English
-
Abstract:
Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen deprivation therapy. PSMA has been a topic of interest during the past decade for both diagnostic and therapeutic targets. Radioligand therapy (RLT) utilizes the delivery of radioactive nuclides to tumors and tumor-associated targets, and it has shown better efficacy with minimal toxicity compared to other systemic cancer therapies. Nuclear medicine has faced a new turning point claiming theranosis as the core of academic identity, since new RLTs have been introduced to clinics through the official new drug development processes for approval from the Food and Drug Administration (FDA) or European Medical Agency. Recently, PSMA targeting RLT was approved by the US FDA in March 2022. This review introduces PSMA RLT focusing on ongoing clinical trials to enhance our understanding of nuclear medicine theranosis and strive for the development of new radiopharmaceuticals.
